Higher all-cause hospitalization among patients with chronic hepatitis C: the Chronic Hepatitis Cohort Study (CHeCS),

E H Teshale1, J Xing2, A Moorman2

  • 1Division of Viral Hepatitis, CDC, Atlanta, GA, USA. eht4@cdc.gov.

Insights

Patients with chronic hepatitis C virus (HCV) infection experience significantly higher hospitalization rates, nearly 3.7 times greater than the general population. This underscores the substantial healthcare burden and costs associated with HCV.

Area of Science:

  • Hepatology
  • Public Health
  • Health Economics

Background:

  • Chronic hepatitis C virus (HCV) infection leads to high hospitalization rates in the U.S.
  • The full healthcare burden of HCV-related hospitalizations remains unclear.

Purpose of the Study:

  • To determine and compare all-cause hospitalization rates between patients with chronic HCV infection and matched health system patients.
  • To identify the primary reasons for hospitalization in chronic HCV patients versus the general population.

Main Methods:

  • Analysis of data from the Chronic Hepatitis Cohort Study (2006-2013).
  • Propensity score matching (PSM) used to compare 10,131 chronic HCV patients with 20,262 health system patients.
  • PSM accounted for site, gender, race, age, and household income.

Main Results:

  • All-cause hospitalization rates were 27.4 per 100 person-years (PY) for HCV patients vs. 7.4 per 100 PY for controls.
  • HCV patients had a 3.7-fold higher all-cause hospitalization rate.
  • HCV patients were significantly more likely to be hospitalized for liver-related conditions (RR = 24.8).

Conclusions:

  • Patients with chronic HCV infection face substantially higher hospitalization rates and associated healthcare burdens.
  • Findings highlight the significant economic and clinical impact of chronic HCV infection.
  • Effective HCV management is crucial to reduce hospitalization and healthcare costs.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
7
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
249
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
4.8K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
329
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
331
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
735